Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer
Doctors are learning that many early prostate cancers grow very slowly and aren't immediately life-threatening. While surgery is common, it often causes side effects. Another option is 'active surveillance,' where doctors just monitor the cancer. However, this can be worrying, and sometimes the cancer progresses too much. This study is testing a new treatment called High Intensity Focused Ultrasound (HIFU). HIFU aims to destroy only the cancerous part of the prostate using sound waves, without harming the healthy tissue around it. This could mean fewer side effects than surgery. We're comparing HIFU to active surveillance to see if it's a safe and effective way to treat these low-risk cancers, helping patients avoid surgery's side effects while still properly managing their cancer.
At a glance
What is this study about?
When prostate cancer is found very early, and it's a type that isn't expected to grow quickly or spread, doctors have a few choices. One common choice is a big operation to remove the whole prostate, which can cure the cancer but often leads to problems like difficulty with urine control or sexual function. Another approach is called 'active surveillance.' This means doctors regularly check on the cancer with tests and scans, but don't treat it right away. The idea is to only step in with treatment if the cancer starts to get worse. While this avoids surgery immediately, it can be very stressful for patients to know they have cancer but aren't being actively treated.
This study is looking at a new type of treatment called High Intensity Focused Ultrasound, or HIFU. Think of it like using very focused sound waves, much like those used in scans, but much stronger. These sound waves can be aimed directly at the cancerous part of the prostate to heat and destroy only those cells, leaving the rest of the prostate and surrounding healthy tissues untouched. The hope is that by targeting only the cancer, HIFU can get rid of the disease with far fewer side effects than traditional surgery.
We want to see if HIFU can give people with these early, low-risk prostate cancers a good treatment option that isn't as harsh as surgery, but also isn't as worrying as just watching and waiting. The study will compare HIFU to active surveillance to understand how well it works and if it genuinely has fewer side effects. This research could help many men make a better choice about their prostate cancer care in the future.
Key takeaways
- This study compares a new focused sound wave treatment (HIFU) with active monitoring for early prostate cancer.
- HIFU aims to destroy cancer cells with fewer side effects than traditional surgery.
- Participants will be randomly assigned to either HIFU or active surveillance.
- The study focuses on men with low-risk prostate cancer.
- Regular check-ups, scans, and blood tests will be part of the study.
- The goal is to find a treatment that is effective yet kinder on the body.
Who may be eligible?
To join this study, men generally need to be between 50 and 80 years old, with a good expectation of living for at least another five years. It's important that you understand the study well and agree to take part by signing a consent form.
The study is for men with prostate cancer that is still contained within the prostate and is considered low-risk. This means the cancer shouldn't be too large, and it needs to be located in a way that allows the HIFU treatment to safely reach it. Your PSA blood test result should also be fairly low (15ng/ml or less).
There are also reasons why you might not be able to join. For example, if the cancer isn't in a good spot for the HIFU sound waves to reach, or if you have certain medical conditions or implants that would make the treatment unsafe. This includes things like previous radiation treatment to your pelvis, or certain issues with your rectum or urinary tract.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Am I a man between 50 and 80 years old?
- Do I have low-risk prostate cancer that is still contained within the prostate?
- Is my PSA level 15 ng/ml or lower?
- Do I have a good overall health and life expectancy of more than 5 years?
- Have I not had previous radiation treatment to my pelvis?
- Do I have no implants or other conditions that might make HIFU treatment unsafe?
What does participation involve?
If you choose to take part in this study, you'll be randomly assigned to either receive the focused HIFU treatment or to undergo active surveillance. For HIFU, the treatment is typically a one-off procedure. Regardless of which group you're in, you'll have regular check-ups. These will include blood tests to measure your PSA (Prostate-Specific Antigen) levels, scans like MRI, and sometimes prostate biopsies to check on the cancer or the treated area. You'll also be asked to fill out questionnaires to share how you're feeling and if you're experiencing any side effects. These follow-ups will continue over several years so doctors can track your progress and the long-term effects of the treatment or surveillance.
Potential risks and benefits
Locations (14)
- Polyclinique du parc RambotVerified postcodeAix-en-Provence, France
- Clinique Saint-VincentVerified postcodeBesançon, France
- Service d'Urologie, Clinique Tivoli DucosVerified postcodeBordeaux, France
- Groupe Hospitalier Pellegrin - CHUVerified postcodeBordeaux, France
- Service d'Urologie, CHU de Guebwiller ColmarVerified postcodeColmar, France
- Service d'Urologie CHRU de Lille, Hôpital HURIEZVerified postcodeLille, France
- Service d'Urologie Générale de Santé - Hôpital Privé La LouvièreVerified postcodeLille, France
- Service d'Urologie et Chirurgie de la Transplantation, Hôpital Edouard Herriot,Verified postcodeLyon, France
- Service d'urologie Assistance Publique - Hôpitaux de Marseille - Hôpital Marseille NordVerified postcodeMarseille, France
- Département d'Urologie, Institut MontsourisVerified postcodeParis, France
- Centre Hospitalier Lyon SudVerified postcodePierre-Bénite, France
- Clinique Urologique Nantes AtlantisVerified postcodeSaint-Herblain, France
Common questions
What is HIFU?
HIFU stands for High Intensity Focused Ultrasound. It's a treatment that uses powerful, targeted sound waves to heat and destroy cancer cells while trying to protect nearby healthy tissue.
What is active surveillance?
Active surveillance means that instead of starting treatment right away, doctors closely watch your cancer with regular tests and scans. Treatment is only offered if the cancer shows signs of growing or getting worse.
Why is this study important?
This study is important because it's looking for a gentler way to treat early prostate cancer that might avoid the serious side effects of surgery, while still effectively managing the disease.
Will I get to choose my treatment?
No, in this study, participants will be randomly assigned to either receive HIFU or active surveillance. This is done to make sure the comparison between the two groups is fair and unbiased.
What is 'low-risk' prostate cancer?
Low-risk prostate cancer means the cancer is small, slow-growing, and is still contained within the prostate, making it less likely to spread quickly or cause immediate health problems.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.